Trial studying antidepressant s possible role in COVID-19 treatment after discovery by UVA doctor
and last updated 2021-01-27 22:26:56-05
CHARLOTTESVILLE, Va. - A clinical trial is underway to test whether a common drug may help treat COVID-19 following a discovery by a doctor at the University of Virginia School of Medicine.
âIt s kind of a dream for every scientist to make a discovery that can impact human health,â Dr. Alban Gaultier, Neuroscience Professor at University of Virginia School of Medicine told News 3. âIt was kind of by accident.â
Gaultier said the discovery involved the antidepressant, fluvoxamine, also known as Luvox, capable of possibly stopping sepsis.
Sometimes, Becky Angell doesn’t even realize she’s started crying. She’s been a nurse for seven years, and worked in an intensive care unit in Olathe for
January 27, 2021 SHARE
The Washington University in St. Louis community is invited to an online discussion exploring a new proposal aimed at creating more jobs in the St. Louis region during the coming decade.
The STL 2030 Jobs Plan, currently in draft form, focuses on inclusive growth throughout the St. Louis region. It was compiled after international economic development expert Bruce Katz conducted extensive research and interviews. The draft plan calls for the St. Louis metropolitan community to make a commitment to create more high-quality job opportunities while also ensuring all residents have access to those opportunities.
Community, civic, nonprofit and economic leaders including various members of the Washington University community served on committees to help develop the data-driven plan. Now, leaders seek input from across the university during an online discussion from noon-1 p.m. Monday, Feb. 1.
(Image: Shutterstock)
As states and municipalities begin to roll out mass vaccination campaigns, some people have dared to ask: When will it be safe to resume “normal” activities again? For those in most parts of the United States, the risk of COVID-19 infection remains extremely high.
People now have access to better real-time information about infection rates and transmission at the county or city level, but they still need a framework to help them decide what is safe to do. Social distancing and shutting businesses have reduced the number of cases, but there is mounting pressure to reopen businesses and classrooms.
DBusiness Magazine
Damian Kotsis // Photo courtesy of Harness Dickey
Harness Dickey, an intellectual property law firm located in Troy, announced that patent attorneys Charlie Franklin, Damian Kotsis, and Brad Luchsinger have been promoted to principal.
Kotsis, a patent attorney in the firm’s Troy office, works with clients in the life science and chemical industries with a focus in biochemistry, pharmaceuticals, agricultural technology, organic chemistry, and polymer technologies. His clients include Fortune 500 companies, academic institutions, startups, and individual inventors. He’s helped clients obtain patent protection for inventions ranging from cancer therapies to fuel formulations and also assists in the preparation of patentability and freedom to practice opinions, as well as with legal opinions relating to various litigation matters. He earned his J.D. from the University of Detroit Mercy and his Ph.D. in biochemistry and molecular biology from Wayne State Universi